reason report
bottom line gilead report financi result market
close yesterday compani deliv revenu line consensu
estim revenu essenti flat sequenti
compar major varianc
sequenti swing retrospect prior period revenu adjust
hcv hiv product sale european custom without
sequenti chang revenu would grown
yoy report compani hiv product
consensu estim still grew
hiv combin grew compar yoy wherea
rest hiv portfolio declin compar
growth trend new product reassur high penetr
rate alreadi achiev biktarvi suggest product like
deceler sharpli futur period growth profil revert
underli market mid-singl digit gilead hcv product
continu erod declin exagger statutori revenu
price adjust european custom total hcv product sale
line consensu estim
compar compar
patient volum market share hcv categori
appear stabil seem prematur call floor market
given continu eros price mani market gilead
product also declin letairi ranexa erod gener
competit lose compar combin sale
quarterli sale compar
compani car-t product yescarta deliv revenu
flat compar compani cite number
contribut factor yescarta perform increas reimburs
improv long term outcom data increas center initi use
european center would expect result
increas rather flat revenu
averag price-to-earnings large-cap revenu
multipl slower-growth medic co
dcf
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm non-gaap ep ex stock option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate gilead stock market perform price target gilead matur
gener biotech compani search next wave innov growth
compani leader hiv medicin busi increas alreadi domin market
share indic expect hiv product sale grow peak
expect signific eros taf/descovi franchis gilead
also built lead posit hepat medicin busi continu declin
headi peak two franchis believ worth compani
recent share price rest compani pipelin consist mainli late life cycl
product ranexa letairi commerci disappoint zydelig
yescarta kinas inhibitor filgotinib near term compani outlook
much depend result pivot trial nash medicin immedi
inhibitor firsocostat trial disappoint compani stock price could suffer
multipl compress expect compani revenu remain rang
next year earn hover rang level stock seem like
enjoy multipl line ex-growth matur biopharmaceut busi
upsid downsid risk come compani busi develop
capit alloc choic opportun
gilead expens robust oper margin decreas sequenti
compar period year earlier gross margin flat compar prior
period increas compar yoy sg similar
proport sale tax rate also similar forma ep
line consensu estim share count line consensu
manag modestli updat financi guidanc slightli narrow prior rang
revenu guidanc otherwis maintain expens margin tax guidanc
compani pipelin updat surprisingli cursori emphas rel limit
portfolio opportun investor current research invest
filgotinib program advanc toward regulatori file us approv presum
eu japan compani nash portfolio stumbl toward hand decis point
without compel enthusiasm convict compani month week phase ii
data atla studi clarifi whether compani two drug combin suffici
activ justifi larg long expens phase invest despit host trial
yescarta seem unlik gilead competit posit commerci outlook cell therapi
materi improv result compani oncolog program
earli gener unfocus even hiv hbv compani develop effort
invest arent particularli compel hiv capsid inhibitor phase
promis altern treatment strategi hiv overal remain underwhelm
potenti compani pipelin compar size annual research budget
budget equival invest vertex mp alexion
op biomarin op mp combin
hard see valu investor get invest insid gilead
gilead manag confirm compani would oper without unifi head
 chosen divid research clinic develop presum manufactur
among differ evp report ceo without integr perspect singl
head decis buy goe develop
develop integr differ part develop run ceo
offic seem effici approach perenni problem compani
made opposit decis financ role give prior head corpor
develop strategi busi develop andi dickinson addit respons
cfo posit remov tradit oversight deal activ cfo risk
compromis sharehold interest valu servic achiev deal object
natur cfo/head strategy/head bd adam sharehold valu
disciplin capit alloc effect structur bypass tradit independ
oversight provid best cfo industri last decad
instead impos structur expedit deal present review approv execut
ostens board account big small deal capit alloc
gener oversight hasnt offer much reassur recent past kite one
industri expens disappoint recent year turnov
c-suit gilead last month lukewarm perform quarter oper
strateg hard much confid new manag group creat valu
residu cash cash flow compani
base quarter result reduc revenu earn forecast gilead
decreas revenu forecast later year mainli due
reduc sale hiv medicin chang forecast line consensu
consensu expens forecast adjust slightli
higher sg expens quarter futur period compani increas
 budget despit slow sale growth invest expens busi launch
drug one competit market industri jak total expens
forecast increas year base chang overal ep estim
reduc later year new ep estim
lower consensu lower later year
given new estim prevail peer compani multipl compani cash flow
outlook decreas target price maintain market perform
rate gilead stock expect stock rang bound pressur year
end investor guess time size natur compani inevit busi
develop transact transact manag team remain unknown quantiti
abil creat valu gilead healthi balanc sheet strong cash flow
unproven maintain market perform rate gilead stock despit attract
valuat see limit opportun signific upsid year end
price target inc base averag three approach
believ reason basi valu stock today approach trough
price earn multipl larg cap slow-growth medic product busi long term
revenu multipl larg cap medic product stock slow growth outlook discount
cash flow dcf use trough consensu forward earn multipl slow-growth
medic product stock celg appli ep
estim gilead give price altern appli slow-grow large-cap
biopharma product celg rhhbi nv revenu multipl
revenu estim deriv impli valu impli one-year price
target lastli dcf use forecast free cash flow appli
growth rate termin cash flow forecast discount valu back present
wacc give present valu averag three approach
price target
risk view outlook valuat gilead includ major chang label
price reimburs coverag compani exist hiv hcv product emerg
aggress price discount rebat valu eros hiv hcv
categori current forecast failur compani princip pipelin
asset selonsertib nash filgotinib ra ibd advanc develop
commerci opportun better perform valu expect includ
delay limit develop profil adopt competit hiv product
success develop underappreci element compani portfolio gs-
fxr agonist inhibitor follow-on cart indic stronger-than-
expect convers current hiv patient gilead next gener taf-bas hiv treatment
royalti contract revenu
non-gaap cost good sold
share count period basic
guidanc
dilut ep impact relat acqusit stock-
base compens
late stage pipelin program includ
late stage pipelin program exclud
brand
svb leerink llc research compani file
type event
event trial detail
date known
up/down
expect
phase ii result registr
phase ii combin data atla trial
phase result
nda submiss ra
phase i/ii result registr
phase i/ii result
phase i/ii result
phase ii testicular safeti filgotinib result
million
symtuza darunavir/c/f-taf royalti
symtuza darunavir/c/f-taf royalti
svb leerink llc research compani file
million
sale incl emori amort
 total revenu
sg total revenu
profit share total revenu
svb leerink llc research compani file
analysi stock price svb leerink target
method trough price earn multipl larg cap slow growth biopharma compani
trough larg cap valu healthcar stock multipl ep celg
impli valuat ep
number period
equiti
method revenu multipl slow growth outlook larg cap biopharma stock appli
svb leerink revenu estim gilead
comp ex growth larg cap revenu multipl rhhbi
impli valu gilead revenu
share outstand gilead
impli year price base revenu
method dcf base current late stage pipelin product declin flow post
wacc growth termin period
present valu late stage market product flow termin valu
net debt
present valu late stage market product flow
averag method
svb leerink llc partner research compani file factset
